THYQUIDITY (levothyroxine sodium) by Pfizer is synthesis. First approved in 2020.
Drug data last refreshed 14h ago · AI intelligence enriched 2d ago
THYQUIDITY is an oral liquid formulation of levothyroxine sodium, a synthetic thyroid hormone replacement approved by the FDA in November 2020. It treats hypothyroidism by restoring T4 levels, which are converted peripherally to the active T3 form to regulate metabolism and gene transcription. The drug works by binding thyroid receptors in the cell nucleus to activate metabolic pathways.
Low Part D adoption signals a niche formulation strategy; commercial team likely focused on specialty channel penetration rather than mass-market scaling.
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
Worked on THYQUIDITY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
THYQUIDITY offers limited career momentum due to minimal linked job openings and a crowded, commoditized market. Roles are primarily commercial and market access focused, with little opportunity for clinical or scientific advancement.